Paper23040887
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE and 14 others. J Allergy Clin Immunol, 2013. Cited by 146 papers, by iCite.
Cite this record
ConductScience Library. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. Papers, record 23040887. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23040887
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Hypereosinophilic Syndrome | Major topic |
| Adolescent | |
| Adrenal Cortex Hormones | |
| Adult | |
| Aged | |
| Double-Blind Method | |
| Eosinophilia | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Time | |
| Young Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIA AI001130 | Intramural NIH HHS | United States | ZIAAI001130 | PubMed and NIH |
Source NIH RePORTER
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16487232 | Orphan drug development is progressing too slowly. | Br J Clin Pharmacol | 2006 | https://conductscience.org/library/papers/16487232 | PubMed |
| 2 | 18344568 | Treatment of patients with the hypereosinophilic syndrome with mepolizumab. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18344568 | PubMed |
| 3 | 21501869 | Hemophagocytic syndrome associated NK/T nasal type lymphoma presenting as hypereosinophilic syndrome: a case report and literature review. | Leuk Res | 2011 | https://conductscience.org/library/papers/21501869 | PubMed |
| 4 | 17868856 | Lymphocytic variant hypereosinophilic syndromes. | Immunol Allergy Clin North Am | 2007 | https://conductscience.org/library/papers/17868856 | PubMed |
| 5 | 19264687 | Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19264687 | PubMed |
| 6 | 20810155 | Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. | J Allergy Clin Immunol | 2010 | https://conductscience.org/library/papers/20810155 | PubMed |
| 7 | 11799357 | Asthma therapies and Churg-Strauss syndrome. | J Allergy Clin Immunol | 2002 | https://conductscience.org/library/papers/11799357 | PubMed |
| 8 | 22460074 | Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. | J Allergy Clin Immunol | 2012 | https://conductscience.org/library/papers/22460074 | PubMed |
| 9 | 19264686 | Mepolizumab and exacerbations of refractory eosinophilic asthma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19264686 | PubMed |
| 10 | 19910029 | Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. | J Allergy Clin Immunol | 2009 | https://conductscience.org/library/papers/19910029 | PubMed |
| 11 | 17128345 | Rare essentials: drugs for rare diseases as essential medicines. | Bull World Health Organ | 2006 | https://conductscience.org/library/papers/17128345 | PubMed |
| 12 | 21958585 | Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. | J Allergy Clin Immunol | 2011 | https://conductscience.org/library/papers/21958585 | PubMed |
| 13 | 10511609 | Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10511609 | PubMed |
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 146 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42367766 | Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases. | Front Immunol | 2026 | https://conductscience.org/library/papers/42367766 | PubMed |
| 42095000 | Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES. | J Allergy Clin Immunol Glob | 2026 | https://conductscience.org/library/papers/42095000 | PubMed |
| 41322417 | Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence. | Front Immunol | 2025 | https://conductscience.org/library/papers/41322417 | PubMed |
| 40943043 | Paradoxical Use of Benralizumab in Reactive Hypereosinophilia from Toxocariasis and Tuberculosis Co-Infection-Case Report and Literature Review. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943043 | PubMed |
| 40486501 | Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes. | Front Allergy | 2025 | https://conductscience.org/library/papers/40486501 | PubMed |
| 40296395 | Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases. | Lung India | 2025 | https://conductscience.org/library/papers/40296395 | PubMed |
| 40120806 | Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome. | J Allergy Clin Immunol Pract | 2025 | https://conductscience.org/library/papers/40120806 | PubMed |
| 39666063 | Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study. | J Neurol | 2024 | https://conductscience.org/library/papers/39666063 | PubMed |
| 39574910 | Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39574910 | PubMed |
| 39389908 | Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome. | Br J Haematol | 2024 | https://conductscience.org/library/papers/39389908 | PubMed |
| 39389714 | Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis. | Immunol Allergy Clin North Am | 2024 | https://conductscience.org/library/papers/39389714 | PubMed |
| 39234416 | Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis. | J Allergy Clin Immunol Glob | 2024 | https://conductscience.org/library/papers/39234416 | PubMed |
| 38966441 | Hypereosinophilia and Left Ventricular Thrombus: A Case Report and Literature Review. | Cureus | 2024 | https://conductscience.org/library/papers/38966441 | PubMed |
| 37886027 | GEMA 5.3. Spanish Guideline on the Management of Asthma. | Open Respir Arch | 2023 | https://conductscience.org/library/papers/37886027 | PubMed |
| 37648281 | Idiopathic hypereosinophilic syndrome presenting as cardiac tamponade and multiorgan dysfunction. | BMJ Case Rep | 2023 | https://conductscience.org/library/papers/37648281 | PubMed |
| 37419574 | HES and EGPA: Two Sides of the Same Coin. | Mayo Clin Proc | 2023 | https://conductscience.org/library/papers/37419574 | PubMed |
| 37266434 | Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach. | Front Immunol | 2023 | https://conductscience.org/library/papers/37266434 | PubMed |
| 37259416 | Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37259416 | PubMed |
| 37122022 | French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. | Orphanet J Rare Dis | 2023 | https://conductscience.org/library/papers/37122022 | PubMed |
| 37064032 | Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37064032 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| FIP1L1 | 81608 | PubTator's text mining | https://conductscience.org/library/genes/81608 | NCBI Gene |
| GGT1 | 2678 | PubTator's text mining | https://conductscience.org/library/genes/2678 | NCBI Gene |
| IL5 | 3567 | PubTator's text mining | https://conductscience.org/library/genes/3567 | NCBI Gene |
| PDGFRA | 5156 | PubTator's text mining | https://conductscience.org/library/genes/5156 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23040887
GET https://conductscience.org/api/papers/v1/23040887/cited_by?page=2